Inside HDACs with more selective HDAC inhibitors

被引：263

作者：

Roche, Joelle ^{[1
,3
]}

Bertrand, Philippe ^{[2
,3
]}

机构：

[1] Univ Poitiers, Equipe SEVE Sucres & Echanges Vegetaux Environm, Lab Ecol & Biol Interact, CNRS,UMR 7267, F-86073 Poitiers 09, France

[2] CNRS, UMR 7285, Inst Chim Milieux & Mat Poitiers, 4 Rue Michel Brunet,TSA 51106,B28, F-86073 Poitiers 09, France

[3] Reseau Epigenet Canc Pole Grand Ouest, Brest, France

来源：

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2016年 / 121卷

关键词：

Epigenetics; HDAC inhibitors; Synthesis; Molecular modelling; Histone acetylation; HISTONE DEACETYLASE INHIBITORS; SUBEROYLANILIDE HYDROXAMIC ACID; BIOLOGICAL EVALUATION; NITRIC-OXIDE; CLASS-I; STRUCTURAL REQUIREMENTS; ANTICANCER ACTIVITIES; ISOFORM-SELECTIVITY; LARGAZOLE ANALOGS; POTENTIAL THERAPY;

D O I：

10.1016/j.ejmech.2016.05.047

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Inhibitors of histone deacetylases (HDACs) are nowadays part of the therapeutic arsenal mainly against cancers, with four compounds approved by the Food and Drug Administration. During the last five years, several groups have made continuous efforts to improve this class of compounds, designing more selective compounds or compounds with multiple capacities. After a survey of the HDAC biology and structures, this review summarizes the results of the chemists working in this field, and highlights when possible the behavior of the molecules inside their targets. (C) 2016 Elsevier Masson SAS. All rights reserved.

引用

页码：451 / 483

页数：33

共 195 条

[1] Design, synthesis, 3D pharmacophore, QSAR, and docking studies of carboxylic acid derivatives as Histone Deacetylase inhibitors and cytotoxic agents
Abdel-Atty, Mona M.
Farag, Nahla A.
Kassab, Shaymaa E.
Serya, Rabah A. T.
Abouzid, Khaled A. M.
[J]. BIOORGANIC CHEMISTRY, 2014, 57 : 65 - 82
[2] Histone Deacetylase 4 (HDAC4) Inhibitors: A Promising Treatment for Huntington's Disease
Abdel-Magid, Ahmed F.
[J]. ACS MEDICINAL CHEMISTRY LETTERS, 2013, 4 (08): : 692 - 693
[3] A cyclodextrin-capped histone deacetylase inhibitor
Amin, Jahangir
Puglisi, Antonino
Clarke, James
Milton, John
Wang, Minghua
Paranal, Ronald M.
Bradner, James E.
Spencer, John
[J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (11) : 3346 - 3348
[4] HDAC inhibitors in parasitic diseases
Andrews, Katherine T.
Haque, Ashraful
Jones, Malcolm K.
[J]. IMMUNOLOGY AND CELL BIOLOGY, 2012, 90 (01) : 66 - 77
[5] Approximate likelihood-ratio test for branches: A fast, accurate, and powerful alternative
Anisimova, Maria
Gascuel, Olivier
[J]. SYSTEMATIC BIOLOGY, 2006, 55 (04) : 539 - 552
[6] The future of epigenetic therapy in solid tumours-lessons from the past
Azad, Nilofer
Zahnow, Cynthia A.
Rudin, Charles M.
Baylin, Stephen B.
[J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2013, 10 (05) : 256 - 266
[7] Development of a Fluorogenic Probe with a Transesterification Switch for Detection of Histone Deacetylase Activity
Baba, Reisuke
Hori, Yuichiro
Mizukami, Shin
Kikuchi, Kazuya
[J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2012, 134 (35) : 14310 - 14313
[8] Histone deacetylases and cancer
Barneda-Zahonero, Bruna
Parra, Maribel
[J]. MOLECULAR ONCOLOGY, 2012, 6 (06) : 579 - 589
[9] Epigenetic Tailoring for the Production of Anti-Infective Cytosporones from the Marine Fungus Leucostoma persoonii
Beau, Jeremy
Mahid, Nida
Burda, Whittney N.
Harrington, Lacey
Shaw, Lindsey N.
Mutka, Tina
Kyle, Dennis E.
Barisic, Betty
van Olphen, Alberto
Baker, Bill J.
[J]. MARINE DRUGS, 2012, 10 (04) : 762 - 774
[10] Inside HDAC with HDAC inhibitors
Bertrand, Philippe
[J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2010, 45 (06) : 2095 - 2116

← 1 2 3 4 5 6 7 8 9 10 →